The initiation of coverage by Wolfe Research with a Peer Perform rating typically suggests that the analyst believes Pacific Biosciences' stock will perform in line with its industry peers. This neutral rating may not significantly impact the stock price in the short term as it neither predicts outperformance nor underperformance.